Objective: To control the postoperative local recurrence is one of the critical factors to improve prognosis of patients with esophageal carcinoma. The aim of this study is to evaluate the effectiveness of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus. Methods: One hundred and twenty-five patients with stage IIA midthoracic esophageal squamous cell carcinoma who underwent modified Ivor-Lewis esophagectomy between June 1999 and June 2002 were included in the retrospective analysis. All the patients were evaluated within 3 years after surgery to detect tumor recurrence. Kaplan-Meier method was used to calculate the survival rate and logistic regression analysis was performed to identify risk factors of locoregional recurrence. Results: The overall 3-year and 5-year survival rate in all patients was 58.4% and 43.2%, respectively. Tumor recurrence occurred in 61 patients (48.8%) within 3 years after operation. The median disease-free interval was 12.6 months. Thirty-three patients (26.4%) developed locoregional recurrence, 23 patients (18.4%) developed distant recurrence and 5 patients (4.0%) developed locoregional and distant recurrence simultaneously. Locoregional recurrence rate of patients with postoperative radiotherapy was significantly lower than that of those without postoperative radiotherapy ( p < 0.05). Logistic regression analysis showed that adjuvant radiotherapy ( p = 0.007) was an independent risk factor for tumor locoregional recurrence. Cox regression analysis showed that locoregional recurrence but not adjuvant radiotherapy was a relevant prognostic factor of patients with stage IIA esophageal cancer. Conclusions: Modified Ivor-Lewis esophagectomy with two-field lymph node dissection plus adjuvant radiotherapy might be an effective strategy to achieve local control of stage IIA mid-thoracic esophageal squamous cell carcinoma. #
Introduction
In China, esophageal squamous cell carcinoma is one of the most common neoplasms and often occurs in the mid-thoracic esophagus. Surgical resection is the preferred modality for treating this malignancy, while the type of curative operation that should be performed is controversial and the effect of surgical resection leaves much to be desired. It is reported that about half of the patients developed recurrence within 2-3 years after operation, and the main pattern was locoregional recurrence [1, 2] . Therefore, to control locoregional recurrence is one of the key factors to improve the overall survival of mid-thoracic esophageal cancer.
In our department, we usually perform modified IvorLewis esophagectomy with two-field lymph node dissection to treat the mid-thoracic esophageal cancer. Then we advise some patients to receive appropriate adjuvant radiotherapy and/or systemic chemotherapy to reduce tumor metastasis and recurrence. In order to assess the effectiveness of this treatment program, this study focus on the patients with stage IIA (T2N0M0 and T3N0M0) esophageal squamous cell cancer to explore the available means of controlling locoregional recurrence after esophagectomy.
Patients and methods

Patients
There were in total 221 patients with squamous cell carcinoma of the mid-thoracic esophagus who underwent modified Ivor-Lewis esophagectomy with two-field lymph node dissection in our department from June 1999 to June 2002. According to 1997 UICC TNM classification, 125 patients were diagnosed as stage IIA esophageal squamous cell carcinoma (T2N0M0 in 54 patients and T3N0M0 in 71) by postoperative pathology (H&E staining). We retrospectively reviewed the complete clinical data of these patients to evaluate the outcome of surgery and adjuvant therapy, which is depicted in Table 1 .
Surgical indications
(1) The patients had received no preoperative radiotherapy or chemotherapy. (2) The mid-thoracic esophageal squamous cell carcinoma was diagnosed by gastroscopy, with clinical stage I-III. (3) In preoperative assessment, the patient's major organ function was normal, without surgical contraindication. (4) There were no clinical signs of lymph node metastasis (e.g. recurrent laryngeal nerve paralysis, diaphragmatic paralysis or Horner syndrome). (5) In the physical examination, no swollen cervical or supraclavicular lymph node was found, and preoperative chest CT scan or cervical ultrasonography indicated no cervical or supraclavicular lymph node metastasis.
Surgical procedure
With a right anterolateral thoracotomy, the chest was entered through the fourth intercostal space. The azygos vein arch was divided, and the esophagus was dissected from esophagogastric junction to the apex of the chest (the length of proximal and distal margins from the tumor was at least 5 cm). When the tumor invaded outside, the thoracic duct was routinely ligated above the diaphragm. Then an upper midline abdominal incision was made, and the abdomen was explored. During the mobilization of the stomach, the right gastroepiploic vessels and arcades must be preserved. The left gastric artery was divided at its origin. Subsequently, the hiatus was enlarged and the stomach was carried to the chest. An end-to-side esophagogastric anastomosis was performed in the apex of the chest (above the azygos vein arch).
According to Korst lymph node mapping system for esophageal cancer [3] , thoracoabdominal two-field lymph node dissection was performed (Fig. 1) . The fields of lymph nodes dissection were normally including: 2R-right upper paratracheal nodes, 3P-posterior mediastinal nodes, 4R-right lower paratracheal nodes, 7-subcarinal nodes, 8M-middle paraesophageal lymph nodes, 9-pulmonary ligament nodes, 16-paracardial nodes, 17-left gastric artery nodes. Additional lymph node dissection was performed as required, including the celiac nodes, the common hepatic artery nodes, and the splenic artery nodes, etc. At least six retrieved lymph nodes were histologically examined for an accurate nodal classification in all the node-negative cases. We did not dissect lymph nodes along the recurrent laryngeal nerve routinely before we recently began to realize recurrent nerve nodal metastasis might be a predictor of cervical nodal metastasis in thoracic esophageal cancer. Furthermore, no cervical lymphadenectomy was undertaken in this study.
Postoperative adjuvant therapies
In China there are no standard guidelines for postoperative adjuvant treatment for patients with esophageal squamous cell carcinoma, and the treatment program depends on tumor stage, doctor's opinion, and patient's will or economic conditions. In our department, we proposed radiotherapy as the main postoperative adjuvant treatment for pathologic stage IIA (T2N0M0 and T3N0M0) esophageal cancer. In this study, before tumor recurrence 46 patients received adjuvant radiotherapy alone (each in a total dosage of 45-60 Gy to the neck, supraclavicular fossa and mediastinum by accelerator linear); 32 patients received systematic chemotherapy for more than four cycles (mainly 5-FU and cisplatin/carboplatin); 18 patients received combined chemoradiotherapy and 29 patients took neither radiotherapy nor chemotherapy. 
Follow-up examinations
Patients were routinely examined at 3-month intervals for 2 years and at 6-month intervals thereafter. During each follow-up visit, the patient underwent a clinical evaluation, blood biochemistry examination including tumor markers, and chest radiography. Endoscopy, ultrasonography (US) of the neck and abdomen, and computed tomography (CT) of the neck, thorax, and abdomen were performed at least once a year. More selective investigations such as positron emission tomography (PET), bone scintigraphy, and cerebral CT were carried out based on specific symptomatology, clinical examination, and biochemical profile. Detection of a suspected recurrence at any one site was followed by a thorough detailed investigation to confirm or refute the occurrence and to examine every other site.
Definition of locoregional and distant recurrence
The first recurrence was noted, and any additional recurrence found within one month was considered to have occurred simultaneously. These lesions were classified as locoregional (at the remaining esophagus, the anastomotic site, or the lymph nodes) and distant (in the distant organs, pleura, or peritoneum) recurrence. Although cervical, celiac axis node metastasis is classified as distant in TNM staging, recurrence at these nodes was classified in our study as locoregional because of the manner of tumor spread though the lymphatic system.
Statistical analysis
Follow-up was complete for all 125 patients. All data were collected on a SPSS 10.0 database. The chisquare test was used to evaluate differences in clinicopathologic features. Estimation of survival was calculated using the Kaplan-Meier method, and the statistical differences were analyzed using the log-rank test. Factors with a possible influence on tumor locoregional recurrence were calculated using the logistic regression model. The influence of clinicopathologic variables on survival was assessed by Cox proportional hazards model. A p value of <0.05 was considered statistically significant for all procedures.
Results
Pattern of recurrence
There was no mortality within 30 days. Tumor recurrence occurred in 61 patients (48.8%) during 3 years after operation. There were 43 men and 18 women, and the median age was 58 years (range 42-76 years). Thirty-three patients (26.4%) developed locoregional recurrence; 23 patients (18.4%) developed distant recurrence, and 5 patients (4.0%) developed simultaneous locoregional and distant recurrence. The median disease-free interval until recurrence was 12.6 (range 3.0-35.3) months. Of all cases of recurrence, 51 patients had died. The median interval between recurrence and death was 7.8 (range 1.1-23.6) months. The distribution of the first sites of tumor recurrence is shown in Table 2 , and the patterns of recurrence have been depicted in Table 3 . 
Locoregional recurrence
In the present study, the total rate of locoregional recurrence (including simultaneous locoregional and distant recurrence) was 30.4% (38/125). The locoregional recurrence rate in postoperative adjuvant radiotherapy group (including combined chemoradiotherapy) was 20.3% (13/64), in postoperative adjuvant chemotherapy group was 40.6% (13/32), and in adjuvant radiotherapy and chemotherapy group was 41.4% (12/29). The chi-square tests showed that the locoregional recurrence rate in adjuvant radiotherapy group was significantly lower than that in adjuvant chemotherapy group (x 2 = 4.457, p = 0.035) and in neither adjuvant radiotherapy nor chemotherapy group (x 2 = 4.506, p = 0.034). The clinicopathologic risk factors influencing locoregional recurrent disease is shown in Table 1 . Table 4 shows the results of the multivariate analysis of risk factors using logistic regression model for locoregional recurrence. It is demonstrated that postoperative adjuvant radiotherapy (including combined chemoradiotherapy) was a significant factor for locoregional recurrence ( p = 0.007). We did not find a significant correlation between locoregional recurrence and length of tumor, histological differentiation, T status and adjuvant chemotherapy.
Logistic regression analysis
Survival
The overall 3-year and 5-year survival rates of 125 patients were 58.4% and 43.2%, respectively (survival curve shown in Fig. 2 ). The 5-year survival rates in patients with postoperative radiotherapy, chemotherapy, combined chemoradiotherapy and without adjuvant therapy were 52.2%, 40.6%, 55.6% and 24.1%, respectively (survival curve depicted in Fig. 3 ). The log-rank test showed the survival rate of patients with postoperative adjuvant therapy was higher than those without ( p = 0.04); however, there was no significant difference among those three groups of patients with postoperative radiotherapy, chemotherapy and combined chemoradiotherapy ( p = 0.73).
A multivariate analysis, using the Cox regression model, was performed to evaluate the prognostic risk factors for survival of all patients (Table 5) . It is locoregional recurrence ( p = 0.002, HR = 2.239) but not postoperative adjuvant radiotherapy ( p = 0.269, HR = 1.346) that was independent relevant prognostic factor of patients with stage IIA esophageal cancer.
Discussion
The patients in the current study were a select group because of the nature of our referral practice. Most of the patients with postoperative locoregional recurrence died within 1 year, so to control locoregional recurrence might be one of the important measures to improve prognosis of patients with esophageal carcinoma. In order to decrease the locoregional recurrence rate after modified Ivor-Lewis esophagectomy, this study focused on the role of postoperative adjuvant therapy in controlling locoregional recurrence. While in China there are no standard guidelines for postoperative adjuvant treatment for patients with esophageal squamous cell carcinoma, and it depends on tumor stage, doctor's opinion, and patient's will or economic conditions. In our department, we proposed radiotherapy as the main postoperative adjuvant treatment for pathologic stage IIA (T2N0M0 and T3N0M0) esophageal cancer. This paper then is to evaluate the effectiveness of modified IvorLewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma of the midthoracic esophagus. Esophageal carcinoma is an aggressive malignancy with a poor prognosis. It is often far advanced at the time of detection, and only a small number of patients are considered for curative resection and long-term survival. Because of the longitudinal lymphatic drainage through the esophageal submucosal plexus, the mediastinal, abdominal and cervical lymph node metastases of esophageal cancer occurs frequently, regardless of the location of the primary tumor. Lerut T [4] and Ando N [5] reported a 30% incidence of cervical nodal metastases of the middle thoracic esophageal cancer. Some surgeons advocated performing a formal cervical lymphadenectomy as well as a two-field lymphadenectomy (abdomen and chest), but the clinical outcome of three-field lymphadenectomy was yet unsatisfactory. The 5-year survival was about 50%, and more than 40% patients developed tumor recurrence after three-field lymphadenectomy [6, 7] . What's more, due to the serious surgical trauma and more postoperative complications, three-field lymphadenectomy is yet not generally accepted [8] .
There are several surgical approaches for the mid-thoracic esophageal cancer, but no preferred standard approach is generally accepted. In the present study, we performed modified Ivor-Lewis esophagectomy to treat the mid-thoracic esophageal cancer. In our opinion, there are some advantages to this approach: (1) the total thoracic esophagus can be completely exposed in the surgical vision, and it is convenient to remove the lesion and resect the subtotal esophagus; (2) the two-field lymph node dissection (abdomen and chest) is able to be performed; (3) it is easy to observe the thoracic duct and deal with its possible damage; (4) compared to cervical anastomosis, the complications of recurrent laryngeal nerve paralysis and stomal leak are lower [9, 10] . On the other hand, with a right anterior thoracotomy and a midline upper abdominal laparotomy, there is no need to reposition the patient during the operation; furthermore, the thoracic and abdominal components can be done synchronously with two surgical teams. However, when the patients with mid-thoracic esophageal cancer were elderly, or their major organ function was relatively poor, we usually choose left transthoracic esophagectomy and esophagogastric anastomosis above the aortic arch.
Compared with three-field lymph node dissection, the biggest drawback of Ivor-Lewis esophagectomy is that cervical lymph node metastatic lesion would be out of reach. Some studies showed that locoregional lymph nodes recurrence was the main pattern of tumor recurrence after Ivor-Lewis esophagectomy with two-field lymph node dissection. Dresner and Griffin [1] reported a 5.7% of cervical node recurrence after Ivor-Lewis esophagectomy, and we reported a 7.1% incidence in our previous study [2] , which were close to that after three-field lymph node dissection on some reports [7, 11] . At present, with the development of radiotherapy technology, radiotherapy has already been an important treatment for esophageal cancer, especially for cervical and upper thoracic esophageal cancer. Can we then suppose is it possible for postoperative adjuvant radiotherapy to substitute additional cervical lymph node dissection?
In our study, the patients were all with stage IIA (T2N0M0 and T3N0M0) esophageal cancer, and postoperative pathology identified negative proximal, distal and lateral incisal margins. So R0 resection was achieved and the relevant adverse effects on tumor locoregional recurrence might be avoided. The follow-up results demonstrated that 30.4% patients developed locoregional recurrence (including simultaneous locoregional and distant recurrence), which was the main pattern of tumor recurrence after modified Ivor-Lewis esophagectomy with two-field lymph node dissection. The mediastinal node recurrence was most common (20.0%) followed by cervical node recurrence (9.6%). The locoregional recurrence rate in adjuvant radiotherapy group was significantly lower than that in adjuvant chemotherapy group and in both adjuvant radiotherapy and chemotherapy group. Logistic regression analysis showed that postoperative adjuvant radiotherapy was a significant independent relevant factor for tumor locoregional recurrence. The 5-year survival of the patients with modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy was 52.2%, which was similar to that of the patients with three-field lymph node dissection [7, 11] . So it appeared that the effect on local controlling of esophageal carcinoma by two-field lymph node dissection plus adjuvant radiotherapy would be approximately equal to that by three-field lymph node dissection.
However, Cox regression analysis demonstrated that locoregional recurrence was an independent prognostic factor of patients with stage IIA esophageal cancer, but not adjuvant radiotherapy. Postoperative adjuvant radiotherapy might have significant impact on controlling locoregional recurrence, but have relatively less effect on improving survival. Yamamoto et al. [12] reviewed the outcome of 89 patients who underwent esophagectomy with systematic dissection of regional lymph nodes to reevaluate postoperative radiotherapy for thoracic esophageal carcinoma. They found the locoregional control rate was significantly better for those who had undergone postoperative radiotherapy, and concluded that postoperative radiotherapy still played an important role as adjuvant treatment. Other authors [1, 7] reported that postoperative adjuvant therapies, including radiotherapy and chemotherapy, do not influence the pattern of recurrence and do not improve survival. Since the influence of postoperative adjuvant radiotherapy was controversial and our trail was retrospective, non-randomized and uncontrolled, we cannot draw definitive conclusions regarding the sufficiency of adjuvant radiotherapy as a substitute for three-field lymphadenectomy.
The effect of chemotherapy to treat esophageal cancer is not certain now. Our study showed that the role of postoperative adjuvant chemotherapy in local controlling of esophageal cancer and improving survival was unsatisfactory. Ando et al. [13] reported a randomized multicenter trial to determine whether postoperative adjuvant chemotherapy improves outcome in patients with esophageal squamous cell carcinoma undergoing radical surgery. The results showed that postoperative adjuvant chemotherapy with cisplatin and fluorouracil is better able to prevent relapse in patients with esophageal cancer than surgery alone, but the patients in their study were mainly pN1 subgroup. In the pN0 subgroup, the 5-year disease-free survival in surgery plus chemotherapy group was not significant better than that in the surgery-alone group. However, with more and more new chemotherapeutic drugs discovered and new programs applied, chemotherapy might play a more prominent role in reducing recurrence of esophageal carcinoma than before.
However, as new NCCN esophageal cancer guidelines in 2007 point out, the patients with node-negative squamous cell carcinoma after R0 resection should be observed, for which we cannot get consent. But some studies [14, 15] reported that even though in patients with pN0 tumor defined by routine pathologic examination, lymph nodes micrometastasis was still found in about 40% patients by immunohistochemistry or molecular biology. Therefore, we recommend postoperative adjuvant therapy, especially radiotherapy, to the patients with stage IIA (T2N0M0 and T3N0M0) esophageal squamous cell carcinoma, while the certain effectiveness should be verified by large-scale randomized clinical study. And now accordingly, a randomized controlled trial comparing two-field lymphadenectomy (including recurrent nerve lymph nodes dissection) plus postoperative adjuvant therapy with three-field lymphadenectomy is ongoing.
In conclusion, 48.8% of the patients with stage IIA midthoracic esophageal squamous cell carcinoma experienced tumor recurrence within 3 years after modified Ivor-Lewis esophagectomy. The main pattern of recurrence was locoregional recurrence, and the postoperative adjuvant radiotherapy would be beneficial in reducing the locoregional recurrence. Through this retrospective study, we are of the opinion that modified Ivor-Lewis esophagectomy with twofield lymph node dissection plus adjuvant radiotherapy might be an effective strategy to achieve local control of stage IIA mid-thoracic esophageal squamous cell carcinoma.
